Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery

Sponsor
Fort Belvoir Community Hospital (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT01097525
Collaborator
Walter Reed National Military Medical Center (U.S. Fed), US Army Night Vision and Electronic Sensors Directorate (Other)
224
2
4
54
112
2.1

Study Details

Study Description

Brief Summary

To determine the effect of two types of wavefront modalities (WFG vs. WFO) and two types of refractive surgery (PRK vs. LASIK) on visual and military task performance after laser refractive surgery.

Condition or Disease Intervention/Treatment Phase
  • Procedure: WFG PRK
  • Procedure: WFG LASIK
  • Procedure: WFO PRK
  • Procedure: WFO LASIK
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
224 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery
Study Start Date :
Apr 1, 2010
Actual Primary Completion Date :
Oct 1, 2014
Actual Study Completion Date :
Oct 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Wavefront guided (WFG) PRK

Procedure: WFG PRK

Active Comparator: WFG LASIK

Procedure: WFG LASIK

Active Comparator: Wavefront optimized (WFO) PRK

Procedure: WFO PRK

Active Comparator: WFO LASIK

Procedure: WFO LASIK

Outcome Measures

Primary Outcome Measures

  1. visual outcomes [12 months postoperatively]

    Visual outcomes will be measured in terms of: number of eyes achieving uncorrected visual acuity (UDVA) 20/20 or better. number of eyes maintaining one Snellen line of corrected distance visual acuity (CDVA). number of eyes within 0.50 diopter of manifest spherical equivalent.

  2. objective image quality [12 months postoperatively]

    as measured by wavefront aberrometry

  3. military task performance [6 months postoperatively]

    as measured by threshold target identification and night firing range

  4. visual performance [12 months postoperatively]

    as measured by contrast sensitivity

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Normal, healthy active adults with access to medical care at Walter Reed Health Care System.

  2. Male or female at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.

  3. Myopic spherical manifest refractive error from -1.00D up to -10.00D inclusive, with no more than 4.00D of manifest cylinder refractive error.

  4. Inclusion based on pre-op Central Corneal Thickness (CCT) will be assessed according to Residual Stromal Bed Thickness

  5. BSCVA of at least 20/20 in the study eye.

  6. Soft contact lens users must have removed their lenses at least two weeks prior to baseline and follow-up measurements.

  7. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four weeks prior to baseline and follow-up measurements.

  8. Refractive stability must be documented by previous refractions. Spherical and cylindrical portion of the manifest refraction must not have varied by more than 0.50 diopters over the previous 12 months.

  9. Exhibits strong motivation for keeping the follow-up visits.

  10. Available for evaluation at Walter Reed during the 1 year follow-up period

  11. If selected, willing and available to undergo testing at Ft. Belvoir during the study period.

  12. All service members must have a signed command authorization to receive government sponsored refractive surgery. The signed command authorization will be included in the original application.

  13. Access to transportation to meet follow-up requirements.

Exclusion Criteria:
  1. Residual, recurrent or active ocular diseases or congenital corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, anterior basement membrane disease, recurrent erosions, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.

  2. History of any previous eye surgery or trauma, including previous refractive surgery.

  3. Dry eye as reflected by Schirmer's test, subjective complaints or symptoms of dry eye, findings during slit lamp exam that would be consistent with dry eye (e.g. superficial punctuate keratitis).

  4. Corneal thickness insufficient to allow the residual remaining stromal bed to be no less than 300 microns in each eye. The residual stromal bed thickness will be determined by subtracting both the LASIK flap thickness and depth of the ablation from the total central corneal thickness measured by pachymetry.

  5. Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. This is standard of care exclusion for refractive surgery at the Walter Reed Refractive Surgery Center because of the medications that are routinely given as part of the procedures. Standard of care analgesia consists of medications (e.g. narcotics) labeled as Pregnancy Category "C" by the FDA. Teratogenic effects are not known, however, physical dependence in the neonate may occur if the mother is given narcotics. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy.

  6. Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).

  7. Significant corneal neovascularization.

  8. Progressive myopia or keratoconus.

  9. Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.

  10. Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.

  11. Any physical or mental impairment which would preclude participation in any of the examinations.

  12. Inability to meet the mandated follow-up visit schedule for any reason such as duty hours, impending deployments, or PCS.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Walter Reed National Military Medical Center Bethesda Maryland United States 20889
2 Fort Belvoir Community Hospital Fort Belvoir Virginia United States 22060

Sponsors and Collaborators

  • Fort Belvoir Community Hospital
  • Walter Reed National Military Medical Center
  • US Army Night Vision and Electronic Sensors Directorate

Investigators

  • Principal Investigator: Kraig S Bower, MD, The Wilmer Eye Institute, Johns Hopkins University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
LTC Bruce Rivers, Director, Warfighter Refractive Eye Surgery Program and Research Center at FT Belvoir, Fort Belvoir Community Hospital
ClinicalTrials.gov Identifier:
NCT01097525
Other Study ID Numbers:
  • 20481
First Posted:
Apr 1, 2010
Last Update Posted:
Mar 13, 2015
Last Verified:
Mar 1, 2015
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 13, 2015